|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
33.140 -0.740 (-2.184%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 21,790,018 | 16.678% | 18,675,371 | 17,034,255 | 15,268,660 | 10,290,050 |
| Cost of Sales | (11,771,506) | 6.775% | (11,024,551) | (10,206,354) | (8,544,646) | (5,461,153) |
| Gross Profit | 10,018,512 | 30.947% | 7,650,820 | 6,827,901 | 6,724,014 | 4,828,897 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (205,333) | 35.284% | (151,779) | (319,970) | (258,525) | (156,667) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 7,256,907 | 50.110% | 4,834,398 | 4,173,803 | 5,357,771 | 3,993,119 | |
| Taxation | (1,523,680) | 71.387% | (889,027) | (603,179) | (807,865) | (484,538) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (824,884) | 39.979% | (589,290) | (170,895) | (129,620) | (120,103) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,908,343 | 46.252% | 3,356,081 | 3,399,729 | 4,420,286 | 3,388,478 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (251,523) | 30.472% | (192,779) | (60,690) | (43,093) | (18,835) |
| Depreciation & Amortisation | 1,740,740 | 4.914% | 1,659,205 | 1,385,662 | 1,042,990 | 703,098 |
| Directors' Emoluments | -- | -- | 135,735 | 132,940 | 105,824 | 66,590 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 122.000 | 48.780% | 82.000 | 82.000 | 106.000 | 81.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.278 | 1.121 | 1.328 | 0.822 |
| NBV per share ($) | 11.430 | -- | 10.185 | 9.473 | 8.295 | 7.579 |
| Remarks: | Real time quote last updated: 25/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,908,343 |
| %Change | 46.252% |
| EPS / (LPS) | RMB 1.220 |
| NBV Per Share (¥) | RMB 11.430 |